138 related articles for article (PubMed ID: 12517441)
41. Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides.
Mannon RB; Nataraj C; Pisetsky DS
Cell Immunol; 2000 Apr; 201(1):14-21. PubMed ID: 10805969
[TBL] [Abstract][Full Text] [Related]
42. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
Adamsson J; Lindblad M; Lundqvist A; Kelly D; Holmgren J; Harandi AM
J Immunol; 2006 Apr; 176(8):4902-13. PubMed ID: 16585586
[TBL] [Abstract][Full Text] [Related]
43. Recent advances in immunostimulatory CpG oligonucleotides.
Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
[TBL] [Abstract][Full Text] [Related]
44. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
Kandimalla ER; Bhagat L; Li Y; Yu D; Wang D; Cong YP; Song SS; Tang JX; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6925-30. PubMed ID: 15860583
[TBL] [Abstract][Full Text] [Related]
45. Cysteine-tailed class I-binding peptides bind to CpG adjuvant and enhance primary CTL responses.
Wettstein PJ; Borson ND; Park JG; McNallan KT; Reed AM
J Immunol; 2005 Sep; 175(6):3681-9. PubMed ID: 16148113
[TBL] [Abstract][Full Text] [Related]
46. The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides.
Zhu FG; Reich CF; Pisetsky DS
Immunology; 2001 Jun; 103(2):226-34. PubMed ID: 11412310
[TBL] [Abstract][Full Text] [Related]
47. Phosphorothioate oligonucleotides: looking for the motif(s) possessing immunostimulatory activities in humans.
Brugnolo F; Annunziato F; Sampognaro S; Manuelli C; Cosmi L; Romagnani S; Maggi E; Parronchi P
Adv Exp Med Biol; 2001; 495():261-4. PubMed ID: 11774576
[No Abstract] [Full Text] [Related]
48. Beyond danger: unmethylated CpG dinucleotides and the immunopathogenesis of disease.
Goldberg B; Urnovitz HB; Stricker RB
Immunol Lett; 2000 Jul; 73(1):13-8. PubMed ID: 10963805
[TBL] [Abstract][Full Text] [Related]
49. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
[TBL] [Abstract][Full Text] [Related]
50. Towards optimal design of second-generation immunomodulatory oligonucleotides.
Kandimalla ER; Yu D; Agrawal S
Curr Opin Mol Ther; 2002 Apr; 4(2):122-9. PubMed ID: 12044033
[TBL] [Abstract][Full Text] [Related]
51. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
52. Medicinal chemistry and therapeutic potential of CpG DNA.
Agrawal S; Kandimalla ER
Trends Mol Med; 2002 Mar; 8(3):114-21. PubMed ID: 11879771
[TBL] [Abstract][Full Text] [Related]
53. Immunostimulatory oligonucleotides: ready for immunotherapy prime time!
Tam YK
J Hematother Stem Cell Res; 2003 Oct; 12(5):467-71. PubMed ID: 14594503
[No Abstract] [Full Text] [Related]
54. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA.
Lee KW; Jung J; Lee Y; Kim TY; Choi SY; Park J; Kim DS; Kwon HJ
Mol Immunol; 2006 May; 43(13):2107-18. PubMed ID: 16442622
[TBL] [Abstract][Full Text] [Related]
55. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides.
Matsuoka N; Nishikawa M; Mohri K; Rattanakiat S; Takakura Y
J Control Release; 2010 Dec; 148(3):311-6. PubMed ID: 20887761
[TBL] [Abstract][Full Text] [Related]
56. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.
Sparwasser T; Koch ES; Vabulas RM; Heeg K; Lipford GB; Ellwart JW; Wagner H
Eur J Immunol; 1998 Jun; 28(6):2045-54. PubMed ID: 9645386
[TBL] [Abstract][Full Text] [Related]
57. Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs.
Kandimalla ER; Zhu FG; Bhagat L; Yu D; Agrawal S
Biochem Soc Trans; 2003 Jun; 31(Pt 3):654-8. PubMed ID: 12773176
[TBL] [Abstract][Full Text] [Related]
58. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
59. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide.
Chen L; Arora M; Yarlagadda M; Oriss TB; Krishnamoorthy N; Ray A; Ray P
J Immunol; 2006 Aug; 177(4):2373-83. PubMed ID: 16887999
[TBL] [Abstract][Full Text] [Related]
60. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
